TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study

Inclusion Criteria:

1. Adult pre-menopausal individuals with regular menstrual cycles (defined as menstrualbleeding every 24 to 38 days)

2. Diagnosed with acute VTE on objective imaging;

3. Within two weeks of starting treatment with therapeutic dose anticoagulation;

4. Planned treatment of at least 3 months of therapeutic dose anticoagulation.

5. Written informed consent in accordance with federal, local and institutionalguidelines.

Exclusion Criteria:

1. Hypersensitivity or allergy to TXA

2. Active major bleeding other than menstrual bleeding

3. Use of hormonal contraceptives

4. Known history of thrombosis and antiphospholipid syndrome (including those patientsthat are triple positive for lupus anticoagulant, anticardiolipin antibodies, andanti-beta 2-glycoprotein I antibodies.

5. Known renal insufficiency

6. Pregnant or breastfeeding

7. Use of other thrombotic agents

8. Under 18 years of age

9. Patient is unable to provide informed consent (lacking capacity, language etc)